Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell Carcinoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The investigators propose a phase II signal-finding study, TRIFECTA-SCC, to determine whether four 100 mg IV every 6 week doses of vilastobart plus six every 4 week doses of Opdualag with induction radiotherapy can lead to ≥50% 6-month progression-free survival for patients with recurrent and/or metastatic squamous cell carcinoma. Patients with pathology-confirmed squamous cell carcinoma, previously untreated in the recurrent and/or metastatic setting, and adequate organ function will be included.
Epistemonikos ID: 265909be745c2b7781a375df39c7162f5a9dda8a
First added on: Oct 28, 2026